摘要
目的 分析2型糖尿病(T2DM)患者亚临床甲状腺功能减退症(SCH)与内脏脂肪面积(VFA)的相关性。方法 选取2021年7月至2022年9月于兰州大学第一医院内分泌科住院治疗的T2DM患者559例,根据促甲状腺激素(TSH)水平将其分为T2DM合并SCH组(75例)和单纯T2DM组(484例),比较两组血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血脂异常率、体重指数(BMI)、VFA、皮下脂肪面积(SFA)、VFA/SFA、Android区域脂肪比例(A)、Gynoid区域脂肪比例(G)、A/G、躯干脂肪百分比(TF%)、全身脂肪百分比(BF%)的差异,采用二元logistic回归模型分析T2DM合并SCH的影响因素。结果 T2DM合并SCH组女性占比、TC、LDL-C、VFA、A、G、TF%、BF%水平高于单纯T2DM组,差异有统计学意义(P<0.05)。二元logistic回归校正模型分析结果显示,校正混杂因素后,VFA为T2DM合并SCH的独立危险因素(OR>1,P<0.05)。结论 T2DM合并SCH患者VFA水平升高,该指标与T2DM患者SCH发生的具有一定的因果关系。
Objective To analyze the relationship between subclinical hypothyroidism(SCH) and visceral fat area(VFA) in patients with type 2 diabetes mellitus(T2DM).Methods A total of 559 patients with T2DM hospitalized in the Department of Endocrinology,the First Hospital of Lanzhou University from July 2021 to September 2022 were selected and divided into T2DM combined SCH group(75 cases) and T2DM alone group(484 cases) according to their thyroid stimulating hormone levels.The differences of serum total cholesterol(TC),triglyceride(TG),high density lipoprotein-cholesterol(HDL-C),low density lipoprotein-cholesterol(LDL-C),dyslipixia rate,body mass index(BMI),VFA,subcutaneous fat area(SFA),VFA/SFA,fat percentage of Android region(A),fat percentage of Gynoid region(G),A/G,trunk fat percentage(TF%),and body fat percentage(BF%) were compared between the two groups.The influencing factors of T2DM combined SCH were analyzed by binary logistic regression model.Results The female proportion,TC,LDL-C,VFA,A,G,TF%,and BF% in T2DM combined SCH group were higher than those in T2DM alone group,and the differences were statistically significant(P<0.05).Binary logistic regression model analysis showed that VFA was an independent risk factor for T2DM combined with SCH after adjusting for confounding factors(OR>1,P<0.05).Conclusion VFA level is increased in T2DM patients with SCH,which has a certain causal relationship with the incidence of SCH in T2DM patients.
作者
李凯
王亚雯
吕小羽
闫俊新
潘斌晶
蔡静
刘靖芳
LI Kai;WANG Yawen;LYU Xiaoyu;YAN Junxin;PAN Binjing;CAI Jing;LIU Jingfang(The First College of Clinical Medicine,Lanzhou University,Gansu Province,Lanzhou 730000,China;Department of Endocrinology,the First Hospital of Lanzhou University,Gansu Province,Lanzhou 730000,China)
出处
《中国医药导报》
CAS
2024年第6期82-85,共4页
China Medical Herald
基金
国家自然科学基金资助项目(81960155)。
